BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
A broad spectrum of tumors develop resistance to classic chemotherapy, necessitating the discovery of new therapies. One successful strategy exploits the synthetic lethality between poly(ADP-ribose) polymerase 1/2 proteins and DNA damage response genes, including BRCA1, a factor involved in homologo...
Saved in:
| Main Authors: | Hana Paculová, Juraj Kramara, Šárka Šimečková, Radek Fedr, Karel Souček, Ondřej Hylse, Kamil Paruch, Marek Svoboda, Martin Mistrík, Jiří Kohoutek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-10-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317727479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage
by: Anell Fernandez, et al.
Published: (2025-05-01) -
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors
by: Clare E. Murray, et al.
Published: (2024-10-01) -
CTP sensing and Mec1ATR-Rad53CHK1/CHK2 mediate a two-layered response to inhibition of glutamine metabolism.
by: Arta Ajazi, et al.
Published: (2022-03-01) -
Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition
by: Danielle G. Carvalho, et al.
Published: (2025-07-01) -
Evaluating the genetic landscape of prostate cancer: new insights from BRCA1/2, ATM and CDK12 mutations
by: Kosuke Takemura, et al.
Published: (2025-02-01)